|
Recent Developments |
|
22-JUN-18
AstraZeneca Pharma India (AZPIL) announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.
16-JUN-17
AstraZeneca Pharma India has received Import and Market permission in Form 45 (Mark... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 5264.60 | 4690.49 | 4737.48 | | Other Income | 68.24 | 58.48 | 92.08 | | Total Income | 5332.84 | 4748.97 | 4829.56 | | Cost of goods sold | 5473.66 | 5284.76 | 4869.43 | | OPBDIT | -140.82 | -535.79 | -39.87 | | PAT | 52.59 | -208.40 | -5.09 | | Gross Block | - | - | - | | Equity capital | 50.00 | 50.00 | 50.00 | | EPS (Rs.) | - | -8.34 | -0.20 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | -2.6 | -11.3 | -0.8 | | Net margin (% of OI) | 1.0 | -4.4 | -0.1 |
|
|
Detailed Financials
|
|
|
|
|
